Latrepirdine not effective in Huntington's disease

Latrepirdine not effective in huntington's disease
Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease, according to a study published online Oct. 29 in the Archives of Neurology.

(HealthDay)—Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease (HD), according to a study published online Oct. 29 in the Archives of Neurology.

Karl Kieburtz, M.D., M.P.H., and colleagues from the HORIZON Investigators of the Study Group and the European Huntington's Disease Network, conducted a six-month, randomized, double-blind study of latrepirdine, 20 mg three times daily, versus placebo in 403 patients with mild-to-moderate HD, across 64 research centers in Australia, Europe, and North America. The effect of latrepirdine on cognition and global function was assessed.

The researchers observed no significant difference between latrepirdine-treated patients and placebo-treated patients in the mean change in the Mini-Mental State Examination score (1.5- and 1.3-point improvement, respectively). There was also no significant difference in the distribution of the Clinician Interview-Based Impression of Change, plus carer interview between the groups (P = 0.84). There were no significant differences on secondary efficacy outcomes measures of behavior, daily function, motor function, and safety. There was a similar incidence of adverse events for latrepirdine- and placebo-treated patients.

"In patients with mild-to-moderate HD and , treatment with latrepirdine for six months was safe and well tolerated but did not improve cognition or global function relative to placebo," the authors write.

Several authors disclosed to pharmaceutical companies, including Medivation and Pfizer, both of which supported the study and manufacture latrepirdine.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Drug shows promise for Huntington's disease

Feb 08, 2010

An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of ...

Reach2HD, a Phase II study in Huntington's disease, launched

Jun 07, 2012

The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) ...

Donepezil found helpful in dementia with lewy bodies

Jul 31, 2012

(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to ...

Recommended for you

The brain's electrical alphabet

Jan 23, 2015

The brain's alphabet is a mix of rate and precise timing of electrical pulses: the observation was made by researchers at the International School for Advanced Studies (SISSA) of Trieste and the Italian Institute ...

Dragnet for epilepsy genes

Jan 23, 2015

An international team of scientists together with the University of Bonn Hospital have taken a new path in the research into causes of epilepsy: The researchers determined the networks of the active genes ...

The molecular biology behind ALS

Jan 23, 2015

UA researchers have identified a molecular defect in motor neurons that may help explain the mechanisms underlying ALS, or Lou Gehrig's Disease.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.